Sugi Predict

Sugi Predict / Compounds / SCHEMBL12621

SCHEMBL12621

SCHEMBL12621

Cc1cc(F)c(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAPGEF4 Q8WZA2 4/20 0.52
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ SELL P14151 1/20 0.40
▸ SELP P16109 1/20 0.40
▸ SELE P16581 1/20 0.40
▸ NFE2L2 Q16236 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ TSHR P16473 1/20 0.37
▸ ACHE P22303 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ APEX1 P27695 1/20 0.33
▸ MPI P34949 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TUBB1 Q9H4B7 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8268053 0.84 RAPGEF4 (0.52) RAPGEF4SELLSELPSELENFE2L2
SCHEMBL13986747 0.84 RAPGEF4 (0.42) RAPGEF4CES2CES1SELLSELP
SCHEMBL10014275 0.84 RAPGEF4 (0.42) RAPGEF4CES2CES1SELLSELP
SCHEMBL12583212 0.82 RAPGEF4 (0.45) RAPGEF4CES2CES1SELLSELP
SCHEMBL25245189 0.80 ALDH1A1 (0.41) RAPGEF4SELLSELPSELENFE2L2
SCHEMBL2209559 0.80 RAPGEF4 (0.39) RAPGEF4SELLSELPSELENFE2L2
SCHEMBL2210414 0.80 SELL (0.57) RAPGEF4CES2CES1SELLSELP
SCHEMBL22102332 0.80 RAPGEF4 (0.39) RAPGEF4SELLSELPSELENFE2L2
SCHEMBL16373692 0.80 RAPGEF4 (0.39) RAPGEF4SELLSELPSELENFE2L2
SCHEMBL26289759 0.80 RAPGEF4 (0.39) RAPGEF4SELLSELPSELENFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1068 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117362188-B Synthesis method of alpha-substituted deuterated amino acid ester 广州医科大学 2025-05-20 — — CN claimed
US-20240218022-A1 ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-04 — — US claimed
CN-117362188-A Synthesis method of alpha-substituted deuterated amino acid ester 广州医科大学 2024-01-09 — — CN claimed
CN-117285426-A Method for simultaneously preparing biphenyl bactericides and topramezone herbicide intermediates 帕潘纳(北京)科技有限公司 2023-12-26 — — CN claimed
CN-101801949-B Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2014-09-24 — — CN claimed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 — — EP claimed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 — — US claimed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 — — CN claimed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 — — EP claimed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US claimed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 — — WO claimed
US-6495540-B2 HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR BRISTOL - MYERS SQUIBB PHARMA COMPANY 2002-12-17 — — US claimed
CN-1335301-A 3-cyano-2, 4, 5-trifluorobenzoic acid and derivatives thereof and application thereof BAYER AG (DE) 2002-02-13 — — CN claimed
US-20020010172-A1 Lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-01-24 — — US claimed
CN-1265644-A Method for preparing 3-cyano-2,4-dihalogen-5-flour-benzoic acid BAYER AG (DE) 2000-09-06 — — CN claimed
EP-4732350-A2 SYSTEMS AND METHODS FOR RECHARGEABLE ENERGY SOURCE SYSTEMS WITH DE-LITHIATED POSITIVE ELECTRODES PURE LITHIUM CORPORATION (US) 2026-04-29 — — EP disclosed
WO-2025231187-A1 LITHIUM METAL ELECTRODE AND BATTERY Pure Lithium Corporation (US) 2025-11-06 — — WO disclosed
EP-0893424-A1 ALPHA,ALPHA-DIFLUOROBENZYL ETHER DERIVATIVES, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAY DEVICES CHISSO CORPORATION (JP) 1999-01-27 — — EP disclosed
CN-1041516-C Method for preparation 3-hydroxy-2,4,5-trifluorbenzoealkyl formate and/or 3-alkoxy-2,4,5-trifluorbenzoealkyformate HOECHST AG (DE) 1999-01-06 — — CN disclosed
CN-1112105-A Method for preparation 3-hydroxy-2,4,5-trifluorbenzoealkyl formate and/or 3-alkoxy-2,4,5-trifluorbenzoealkyformate HOECHST AG (DE) 1995-11-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218022-A1 ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS VIP, SGTA, NGLY1 RAPGEF4 2855/4885CES2 4262/4885CES1 895/4885
US-20020010172-A1 Lactams as inhibitors of A-beta protein production BACE1, APP, APH1A RAPGEF4 2254/4885CES2 1767/4885CES1 1031/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RAPGEF4 1821/4885CES2 2498/4885CES1 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.